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Abstract 33 
 Little is known on the expression of the tumour-associated carbohydrate antigen 34 
sialyl-Tn (STn), in bladder cancer. We report here that 75% of the high-grade bladder 35 
tumours, presenting elevated proliferation rates and high risk of recurrence/progression 36 
expressed STn. However, it was mainly found in non-proliferative areas of the tumour, 37 
namely in cells invading the basal and muscle layers. STn was also found in tumour-38 
adjacent mucosa, which suggests its dependence on a field effect of the tumour. 39 
Furthermore, it was not expressed by the normal urothelium, demonstrating the cancer-40 
specific nature of this antigen. STn expression correlated with that of sialyltransferase 41 
ST6GalNAc.I, its major biosynthetic enzyme. The stable expression of ST6GalNAc.I in 42 
the bladder cancer cell line MCR induced STn expression and a concomitant increase of 43 
cell motility and invasive capability. Altogether, these results indicate for the first time a 44 
link between STn expression and malignancy in bladder cancer. Hence, therapies 45 
targeting STn may constitute new treatment approaches for these tumours.    46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
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1. Introduction 58 
Bladder cancer, the fifth most common cancer in Western society, is a growing 59 
concern, owing to increased incidence during the past years (Ploeg et al., 2009; van 60 
Rhijn et al., 2009). Most of the newly diagnosed bladder cancer cases are superficial, or 61 
low-grade non-muscle invasive papillary tumours, being conservatively treated by 62 
complete transurethral resection of the tumour (Babjuk et al., 2012). However, 63 
approximately half of the patients show a high-percentage of recurrences and an 64 
elevated risk of progression to muscle invasive disease, which correlates with poor 65 
prognosis (Hussain et al., 2009). The risk of recurrence and/or progression is mostly 66 
determined by clinicopathological features (Babjuk et al., 2012). According to the 67 
European Organization for Research and Treatment of Cancer (EORTC), this group 68 
includes high grade (HG) papillary tumours and carcinoma in situ (CIS) and those with 69 
multifocal or recurrent lesions (Babjuk et al., 2012). The evaluation of the nuclear 70 
protein Ki-67 (Ki-67 proliferation index), an established marker of cell proliferation, is 71 
often used to enhance the prognostic accuracy of risk classification given by 72 
clinicopathological features (Margulis et al., 2009; Santos et al., 2003), since it is 73 
considered a surrogate biomarker of bladder cancer aggressiveness, disease recurrence 74 
and progression (Margulis et al., 2009; Santos et al., 2003).  75 
Tumour resection followed by a schedule of intravesical instillations with live 76 
attenuated strains of Mycobacterium bovis (Bacillus Calmette-Guérin, BCG) is the 77 
standard adjuvant therapeutic option for high-risk of recurrence/progression bladder 78 
tumours (Askeland et al., 2012; Babjuk et al., 2012). Although BCG has improved the 79 
management of high-risk patients, 30-40% of cases either show intolerance or relapse 80 
after treatment (Yates and Roupret, 2011). Consequently, these patients require life-long 81 
follow-up and repeated courses of treatment making bladder cancer the costliest to treat 82 
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among solid tumours (Askeland et al., 2012; Dovedi and Davies, 2009; Sievert et al., 83 
2009). Upon therapeutic failure and/or muscle invasion, cystectomy is advocated for 84 
oncological control (Askeland et al., 2012; Dovedi and Davies, 2009; Sievert et al., 85 
2009). Furthermore, at the moment there is a lack of specific biomarkers to target 86 
aggressive cell phenotypes and direct molecular-based therapy, which may be used to 87 
avoid preventive cystectomy (Dovedi and Davies, 2009).   88 
Vaccines using tumour-associated glycans, in association with immunological 89 
boosters, are emerging as potential therapeutic strategies against cancer (Hakomori, 90 
2001; Lakshminarayanan et al., 2012; Ryan et al., 2010; Sorensen et al., 2006). In the 91 
forefront of these antigens is sialyl-Tn (STn; Neu5Ac2-6GalNAc-O-Ser/Thr) 92 
(Gilewski et al., 2007; Julien et al., 2009; Miles et al., 2011). STn has been mostly 93 
observed in tumour-associated mucins due to their high number of potential O-94 
glycosylation sites (Clement et al., 2004; Conze et al., 2010; Julien et al., 2006; Marcos 95 
et al., 2011; Pinto et al., 2012). However, integrins (Clement et al., 2004) and CD44 96 
(Julien et al., 2006), among other proteins, may also carry this posttranslational 97 
modification. Overexpression of STn antigen has been detected in breast (Leivonen et 98 
al., 2001), esophagus (Ikeda et al., 1993), colon (Itzkowitz et al., 1989), pancreas (Kim 99 
et al., 2002), stomach (David et al., 1996; Marcos et al., 2011), endometrium (Inoue et 100 
al., 1991), and ovary (Numa et al., 1995) carcinomas, whereas low or no expression was 101 
observed in the respective normal tissues. STn overexpression was also reported in 102 
several cancer precursor lesions, such as esophageal dysplastic squamous epithelia (Itoh 103 
et al., 1996), gastric intestinal metaplasia (Baldus et al., 1998; Ferreira et al., 2006) and 104 
colonic moderate dysplasia (Cao et al., 1997). 105 
STn is known to influence cell recognition by the immune system (Angata et al., 106 
2007), affect processes as cell cycle, apoptosis, and actin cytoskeleton dynamics, 107 
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decrease cell–cell aggregation and increase extra-cellular adhesion, migration, invasion 108 
(David et al., 1996; Julien et al., 2006; Julien et al., 2005; Pinho et al., 2007) and 109 
metastization (Ozaki et al., 2012). In line with these observations, STn positive (STn+) 110 
cells have been frequently observed at the invasion front of tumours and in peritoneal 111 
and pleural effusions in ovarian cancer patients; yet they are less common in metastatic 112 
lesions than in primary tumours (Davidson et al., 2000). In gastric carcinomas, STn was 113 
correlated with the depth of invasion and metastization (Ikeda et al., 1993), and thus 114 
poor prognosis (Terashima et al., 1998). Conversely, STn was not correlated with the 115 
depth of invasion in studies concerning colorectal (Itzkowitz et al., 1989; Ogata et al., 116 
1998) and breast cancers (Schmitt et al., 1995). However, some contradicting results 117 
have been presented regarding its association with metastasis and decreased survival in 118 
these cancers (Julien et al., 2012). Hence, a recent review suggests that the biological 119 
role of STn in tumour development may be dependent on each cancer type or sub-120 
type(Julien et al., 2012).  121 
Despite these observations, there is little information regarding STn in the 122 
context of bladder cancer. Given its clinical relevance and the fact that there are 123 
available therapies based on this antigen, we addressed the presence of STn in bladder 124 
tumours and the mechanisms underlying its expression.   125 
 126 
2. Materials and Methods 127 
2.1. Patient and sampling 128 
  Formalin-fixed, paraffin embedded (FFPE) tissues were prospectively collected 129 
from 69 patients, mean age of 69 years (age range 45–89), who underwent transurethral 130 
resection (TUR) of the bladder tumour in the Portuguese Institute for Oncology of Porto 131 
(IPO-Porto, Portugal), between July 2011 and May 2012. Based on urothelial carcinoma 132 
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grading and staging criteria of the World Health Organization (WHO), three different 133 
groups were considered (Table 1), low-grade (LG, n=24) and high-grade HG non 134 
muscle-invasive (NMIBC, n=26) and muscle-invasive (MIBC, n=19) bladder cancers. 135 
Of HG NMIBC, 21 were papillary tumours and 5 were carcinoma in situ (CIS). None of 136 
these patients had received prior adjuvant therapy. Six normal urothelium tissues of 137 
necropsied male individuals without bladder cancer history, within the same mean of 138 
age range, were also included. 139 
Additionally, FFPE tissues from 16 radical cystectomy cases including the main 140 
lesion in each specimen, responsible for therapeutic decision, the adjacent mucosa, 141 
which may or may not include a concomitant tumour, and the ureter representing a 142 
distant mucosa, were also studied. Mucosa without visible histopathological alterations 143 
was defined as “histologically normal” mucosa.  144 
All procedures were performed under the approval of the Ethics Committee of 145 
IPO-Porto, after patient’s informed consent. All clinicopathological information was 146 
obtained from patients’ clinical records.  147 
  148 
2.2. Tissue expression of STn and Ki-67 149 
FFPE tissue sections were screened for STn and Ki-67 by 150 
immunohistochemistry using the avidin/biotin peroxidase method. Briefly, 3 m 151 
sections were deparaffinised with xylene, rehydrated with graded ethanol series, 152 
microwaved for 15 min in boiling citrate buffer (10mM Citric Acid, 0.05% Tween 20, 153 
pH 6.0), and exposed to 3% hydrogen peroxide in methanol for 20 min. The expression 154 
of STn was then evaluated using anti-STn mouse monoclonal antibody, clone TKH2 155 
(Kjeldsen et al., 1988), that identifies both single and clustered STn residues (Ogata et 156 
al., 1998), whereas Ki-67 was evaluated using monoclonal mouse anti-human Ki-67 157 
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antibody, clone MIB-1 (Dako). After blockage with BSA (5% in PBS), the antigens 158 
were identified with Vectastain Elite ABC peroxidase kit (Vector Lab) followed by 159 
incubation with 3,3-diaminobenzidine tetrahydrochloride (DAB, Dako). Finally, the 160 
slides were counterstained with hematoxylin for 1 min. Positive and negative control 161 
sections of intestinal metaplasia were tested in parallel. The negative control sections 162 
were performed by adding BSA (5% in PBS) devoid of primary antibody. STn+ tissues 163 
were also treated with a neuraminidase from Clostridium perfringens (Sigma-Aldrich) 164 
as previously described by Marcos et al. (Marcos et al., 2011) in order to remove the 165 
sialic acid. The desialyated samples were thereafter screened for STn. The O-acetylation 166 
of Neu5Ac residues in STn was evaluated after treatment  with 100 mM NaOH at room 167 
temperature for 30 min as described by Ogata et al. (Ogata et al., 1998) prior to 168 
immunohistochemistry with antibody TKH2. 169 
A semi-quantitative approach was established to score the immunohistochemical 170 
labeling based on the intensity of staining and the percentage of cells that stained 171 
positively. The STn and Ki-67 expression were assessed double-blindly by two 172 
independent observers and validated by an experienced pathologist. Whenever there 173 
was a disagreement, the slides were reviewed, and consensus was reached. Tumours 174 
were classified as proliferative whenever Ki-67 expression was higher than 18%, as 175 
described by Santos et al. (Santos et al., 2003).  176 
 177 
2.3. Cell lines culture 178 
The human bladder cancer cell line MCR and the transduced variants of MCR 179 
(MCRnc and MCRSTn+), were grown as described by Videira et al. (Videira et al., 180 
2009b).  181 
 182 
2.4. Generation of STn+ bladder cancer cells 183 
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MCR cells were transduced with a retroviral vector generated with the 184 
ViraPower™ Lentiviral Expression System (Invitrogen), according to manufacturer’s 185 
instructions. The whole coding region of human ST6GalNAc.I was PCR amplified and 186 
cloned in the pLenti6/V5 Directional TOPO cloning vector which drives the expression 187 
of inserted genes through the CMV promoter. A negative control retroviral vector was 188 
prepared with an empty plasmid. After transduction with negative control- or 189 
ST6GalNAc.I-expressing vectors, MCR cells were selected with 4 g.ml-1 blasticidin. 190 
An additional immunomagnetic enrichment of the STn+ cells was performed by using 191 
mouse anti-STn (HB-STn1 clone from Dako), followed by the secondary antibody anti-192 
mouse IgG associated to paramagnetic microbeads (Miltenyi Biotec). The stable 193 
transduction of the enzyme was confirmed by evaluation of ST6GalNAc.I expression 194 
and activity. STn expression was determined by analysis of the mean fluorescence 195 
intensity (MFI) ± SE through flow cytometry analysis using monoclonal antibody 196 
TKH2.  197 
 198 
2.5. Evaluation of STn expression in cell lines 199 
For phenotypic characterization, cells were stained with 1:50 diluted anti-STn 200 
TKH2 monoclonal antibody for 16 hours at 4 ºC, and 1:100 diluted goat fluorescein 201 
isothiocyanate (FITC)-labelled anti-mouse IgG (Dako) for 15 min at 4 ºC in the dark 202 
and then acquired in a FacsCalibur Flow cytometer (Becton Dickinson). Data were 203 
analyzed using the WinMDI v2.9 software (The Scripps Research Institute, San Diego, 204 
CA, USA). 205 
 206 
2.6. Analysis of ST6GalNAc.I expression 207 
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RNA extraction from FFPE sections was performed after deparaffinization of 208 
the tissue using Absolutely RNA FFPE kit (Agilent technologies) while for cell lines it 209 
was used the GenElute Mammalian Total RNA Purification kit and DNAase treatment 210 
(Sigma), according to the manufacturer's instructions. The purity of RNA extracts was 211 
determined based on the A260/A280 ratio. Only ratios between 1.9 and 2.1 were 212 
considered further.  213 
Approximately 250 to 500 ng of total RNA (1 μg for cell lines) was converted 214 
by reverse transcription into cDNA, using the random-primers-based High Capacity 215 
cDNA Archive Kit (Applied Biosystems). The expression levels of ST6GalNAc.I were 216 
determined by TaqMan assay (Applied Biosystems), the reference sequences detected 217 
by each primer/probe set and the Assay ID provided by the manufacturer were the 218 
following: ST6GalNAc1 (NM018414.2/Hs00300842_m1). Real time PCR was 219 
performed in a 7500 Fast Real-Time PCR System using the TaqMan Universal PCR 220 
Master Mix Fast from Applied Biosystems, as described previously by Videira et al. 221 
(Videira et al., 2009a; Videira et al., 2007). During the cDNA exponential amplification 222 
the product formation was proportional to the fluorescence emission resulting from the 223 
TaqMan probe degradation (van der Velden et al., 2003). The ST6GalNAc.I mRNA 224 
levels were normalized for the expression of β-actin, which was taken as a suitable 225 
endogenous control for bladder cancer cells (Videira et al., 2007). The relative mRNA 226 
levels were calculated by adapting the 2-ΔΔCt formula (Livak and Schmittgen, 2001). 227 
 228 
2.7. Evaluation of ST6GalNAc.I activity 229 
MCR cell pellets were homogenized in H2O and the protein concentration was 230 
determined using the RC-DC protein quantification kit (BioRad) according to the 231 
manufacturer’s instructions. Sialyltransferase activity was assayed in whole cell 232 
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homogenates as previously described by Dall’Olio et al. (Dall'Olio et al., 1997) with 233 
some modifications. Briefly, the reaction mixture contained 80 mM sodium cacodylate 234 
buffer pH 6.5, 0.5% Triton X-100, 6μg.μl-1 of asialo bovine submaxillary mucin 235 
(ABSM, prepared by acid desialylation of BSM) as acceptor substrate, 30 μM (1280 236 
Bq) of CMP-[14C]Sia (Amersham) and 2 μg.μl-1 of homogenate proteins. Endogenous 237 
controls were prepared in the absence of acceptor substrate. The enzyme reactions were 238 
incubated at 37 ºC for 2 hours and the acid insoluble radioactivity was measured as 239 
previously described by Dall’Olio et al. (Dall'Olio et al., 1997). The incorporation on 240 
endogenous substrates was subtracted.  241 
 242 
2.8. Cell proliferation measurement 243 
To study their proliferative capacity, cells were labelled with CellTrace™ CFSE 244 
Cell Proliferation Kit (Invitrogen). The MCR cells were resuspended into medium at 245 
final concentration of 1 x 106 cells.ml-1 and incubated with 10 μM CFSE, following the 246 
manufacturer’s instructions. Subsequently, the CFSE-labelled cells were seeded into 24-247 
well microplates, incubated in a 5% CO2 incubator at 37 °C and harvested at 24, 48, 72 248 
and 96 hours post-culture. Flow cytometry using a FACSCalibur (Becton-Dickinson) 249 
was performed and the data collected were analyzed with ModFit LT 3.2 software 250 
(Verity Software House, Topsham, ME), allowing to assess the cell proliferation index 251 
(PI). The PI represents the average number of cells that were originated from a single 252 
cell of the parental generation. The parental generation was set based on the analysis of 253 
data obtained from the cells corresponding to the 24 hours of culture. 254 
 255 
2.9. Analysis of cell motility using a wound-healing assay  256 
Cell motility was tested in a wound-healing migration assay. MCR cells were 257 
seed into 12-well microplates and grown to confluency. A scratch was made in the 258 
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monolayer with a sterile 200 μl pipette tip. After wounding, the suspended cells and 259 
debris were washed away and fresh medium was added. At 0 and 24 hours after 260 
wounding, scratched regions were photographed with an inverted microscope equipped 261 
with a digital camera. 262 
 263 
2.10. Invasion Assay  264 
Invasion assays were performed using BD Biocoat MatrigelTM invasion 265 
chambers, comprised by an 8-m diameter pore size filter coated with a thin layer of 266 
matrigel, and placed in a two-compartment system in a 24-well plate. Prior to each 267 
experiment, filters were re-hydrated in serum-free DMEM medium for 2 h at 37 ºC. 268 
After detachment of subconfluent cells with trypsin/EDTA, cells were suspended in 269 
culture medium supplemented with 5% inactivated FBS, counted and seeded on the 270 
upper side of the matrigel-coated filter at a density of 5 x 104 cells/well. After 24 h at 37 271 
ºC, filters were fixed in 4% paraformaldehyde and non-invading cells, present on the 272 
upper side, were completely removed, to facilitate analysis.  Cells that had invaded the 273 
underside of the filters were mounted in Vectashield+4’,6-diamidino-2-phenylindole 274 
(DAPI, Vector Laboratories, CA, USA), and visualized through a Zeiss Axiovert 200M 275 
fluorescence microscope (Carl Zeiss, Germany). Invasive cells were scored in at least 276 
12 microscopic fields (20x objective) when DAPI-counterstained nuclei passed through 277 
the filter pores.Results are presented as means ± SD for each sample. Invasion levels are 278 
expressed as a ratio of the results obtained with the mock-transfected control cell line. 279 
 280 
2.11. Statistical analysis 281 
Statistical analysis was performed using the Student’s T-test for unpaired 282 
samples. Differences were considered to be significant when p<0.05. A chi-square test 283 
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was used to analyse correlations between clinicopathological features and STn and Ki-284 
67 expressions. 285 
 286 
3. Results  287 
3.1.1. Expression of STn in bladder tumours 288 
STn expression in bladder tumours was evaluated by immunohistochemistry 289 
using mouse monoclonal antibody clone TKH2. As shown in Table 1, STn is not 290 
expressed in the healthy urothelium; conversely 46% of the bladder tumours presented 291 
cells with STn membrane and cytoplasmic staining (32/69) (Figure 1), demonstrating 292 
the tumour-specific nature of this antigen. The removal of sialic acids from the tissue 293 
sections with a -neuraminidase impaired the recognition by TKH2 and confirmed STn 294 
expression.  295 
STn expression was lower in low-grade (LG) NMIBC (21% STn+ tumours; 296 
Figure 1A-B) compared to high-grade lesions (HG; 67%), which include papillary 297 
tumours (76% STn+ tumours; Figure 1C-E), CIS (20% of STn+ tumours; Figure 1F), 298 
and MIBC (74% STn+ tumours; Figure 1G-H). Noteworthy, STn was absent from the 299 
majority of CIS (4/5; 80%) and showed an expression comparable to LG tumours. 300 
Altogether, these results highlight an association between the STn antigen and high 301 
grade NMIBC (p<0.002; Figure 2) as well as with muscle invasive tumours (p<0.03; 302 
Figure 2).   303 
The O-acetylation of sialic acid residues prevents TKH2 from recognizing STn 304 
antigens in certain tissues (Ogata et al., 1998). To exclude this possibility in bladder 305 
cancer, the slides were chemically de-O-acetylated prior to immunohistochemistry. This 306 
procedure did not alter STn expression patterns demonstrating that STn antigens were 307 
not encrypted by O-acetylation.  308 
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 309 
3.1.2. Pattern and extension of STn expression in bladder tumours  310 
The STn antigen presented a focal expression that for the majority of the STn 311 
positive cases (26/36) did not exceeded 15% of the tumour section (Table 1). 312 
Furthermore, in 25% of the STn positive cases (9/36) the antigen was detected in less 313 
than 5% of the tissue (data omitted from Table 1). Higher expression patterns were 314 
restricted to HG papillary NMIBC, where 27% of the cases (7/26) presented STn levels 315 
between 15% and 45% of the tumour section (Table 1) and locally diffuse staining 316 
(Figure1C,D,G). STn was mainly observed in basal layer cells (75% of STn+ cases; 317 
Figure 1A,C-E), but it could be also detected throughout the papillae (Figure  1C-E) and 318 
cells of the luminal surface (Figure 1F) in cases presenting locally diffuse staining. STn 319 
was further observed in cells invading the basal (50% of STn+ of HG NMIBC; Figure 320 
1C-E,G) and muscle layers (57% of STn+ MIBC; Figure 1G,H), suggesting a role in 321 
invasion. 322 
 323 
3.1.3. STn antigen expression in advanced tumours and in the surrounding areas  324 
The STn antigen was also evaluated in a series of radical cystectomy specimens 325 
which included the tumour used for therapeutic decision (termed “main tumour” in 326 
Figure 3) and the tumour-adjacent mucosa. The ureters were included as distant mucosa 327 
(Figure 3). In agreement with the observations from Table 1, STn was detected in 69% 328 
(11/16) of all main tumours as well as in their adjacent mucosa (Figure 3), 329 
independently of their histological classification. Noteworthy, STn was absent from 330 
90% of the distant mucosas of STn positive cases; the only exceptions being a ureter 331 
with pre-neoplastic and another with a neoplastic lesions (Figure 3). These results point 332 
out that the STn+ tumour-adjacent mucosa may display molecular changes similar to 333 
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those of the main lesions. Thus, this antigen may be useful as a marker of field 334 
carcinogenesis in the bladder. 335 
 336 
3.2 Expression of ST6GalNAc.I in bladder tumours 337 
 The presence of STn has been strongly associated with the overexpression of 338 
ST6GalNAc.I in several human malignancies. To assess this event in bladder tumours, 339 
mRNA levels of ST6GalNAc.I gene were analyzed and normalized in relation to -actin, 340 
which proved to be a stable expressed gene in previous studies concerning bladder 341 
tumours (Videira et al., 2007).  As shown by Figure 4, low gene expression levels were 342 
detected in tumours that did not express STn. In addition, the levels of ST6GalNAc.I 343 
increased with the expression of STn, and were significantly higher in the tumours with 344 
STn expression superior to 15%. Figure 4 also shows that this behaviour was similar in 345 
LG and HG tumours. However, as a result of higher STn expression, the average 346 
ST6GalNAc.I mRNA levels were more elevated in HG (53%) tumours than LG (9%). 347 
These observations suggest that overexpression of ST6GalNAc.I gene is one of the main 348 
events leading to STn expression in bladder tumours.  349 
 350 
3.3. STn expression and tumour proliferation 351 
 As shown above, the expression pattern of STn correlates with HG tumours, 352 
known to present elevated proliferation rates (Margulis et al., 2009; Santos et al., 2003). 353 
To assess a possible association between STn and proliferation, 24 cases from the initial 354 
series of 69 bladder tumours, comprehending 12 LG and 12 HG tumours (7 NMIBC, 355 
none of them CIS, and 5 MIBC), were screened for STn and Ki-67 expression. Tumours 356 
presenting Ki-67 expression superior to 18% were classified as proliferative. As 357 
highlighted by the graphical matrix in Figure 5A, 8% (1/12) LG and 75% (9/12) HG 358 
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cases showed elevated Ki-67, confirming the higher proliferation of HG tumours 359 
(p<0.0012). Similarly, Figure 5A also shows an association between proliferative 360 
phenotypes and STn expression (p<0.001). However, in all STn positive cases, the 361 
examination of sequential sections revealed that STn antigen expression was mainly 362 
seen in areas that did not express Ki-67 (Figure 5A), although some overlap was present 363 
in 25% of the cases (3/12; Figure 5B). This indicates that the STn antigen is mostly 364 
expressed in non-proliferative areas of the tumour. Nevertheless, the majority of the 365 
non-proliferative tumours also did not express STn (12/14), demonstrating an 366 
interdependence between both phenomena.  367 
 368 
3.4. In vitro assessment of the biological significance of STn expression 369 
  370 
3.4.1. Development of a high-grade bladder cancer cell line overexpressing STn  371 
To further corroborate the role of ST6GalNAc.I in the expression of STn antigen 372 
by bladder cancer cells, we induced the overexpression of ST6GalNAc.I in a bladder 373 
cancer cell line. The MCR bladder cell line, that showed negligible expression of 374 
ST6GalNAc.I and no STn (data not shown), was transduced with a lentivirus expressing 375 
the coding region of the human ST6GalNAc.I gene. The obtained cell line variant, 376 
herein named MCRSTn+, showed markedly increased expression of ST6GalNAc.I 377 
mRNA levels (Figure 6A). It also showed significantly higher sialyltransferase activity 378 
towards the ABSM, a substrate for the ST6GalNac.I enzyme, when compared with the 379 
negative control cell line (MCRnc) transduced with void lentivirus (Figure 6A). The 380 
overexpression of STn antigen by MCRSTn+ cell line variant was confirmed by flow 381 
cytometric analysis (Figure 6B).  382 
 383 
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3.4.2. STn influence on cell proliferation, migration and invasion  384 
 STn expression was correlated with tumours with higher proliferative indexes 385 
(Figure 5). To assess the influence of STn in proliferation, MCR cells (MCRnc and 386 
MCRSTn+) were cultured for 48, 72 and 96 hours and then evaluated in relation to their 387 
proliferation index. The comparison between the two cell line variants showed that the 388 
proliferation index of MCRSTn+ cells was generally higher than the index of  MCRnc 389 
cells, although only statistically different at 72 hours of culture (p<0.05; Figure 7). 390 
However, this effect was no longer significant at 96 hours of culture (Figure 7).  391 
STn positive cells were observed invading the basal and muscle layers (Figure 1 392 
and 2) and in the adjacent mucosa of advanced stage bladder tumours (Figure 5), 393 
suggesting a correlation of STn with invasion and migration. Thus, the influence of STn 394 
expression in MCR cell invasion was assessed using the Matrigel invasion assay. Our 395 
results evidence that MCR cells transduced with ST6GalNAc.I (MCRSTn+) are 396 
approximately four folds more invasive than bladder cells transduced with the negative 397 
control (MCRnc; Figure 8A). The effect of STn expression on cell migration was 398 
estimated by a wound-healing assay. Therefore, uniform scratches were made in 399 
confluent monolayers of MCRnc and MCRSTn+ cell lines and the capability of the cells 400 
to migrate and fill the scratches was monitored. As observed in Figure 8A, by 24 hours 401 
after wounding, the MCRSTn+ cells had almost completely covered the empty space. 402 
Conversely, the negative control, MCRnc cells, displayed a large “gap”, thus 403 
demonstrating their lower capability to closure the wound. Our results evidence that 404 
MCR cells expressing STn present increased invasion and wound repair capacities.  405 
 406 
4. Discussion 407 
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The STn antigen is highly expressed by several human carcinomas and 408 
preneoplastic lesions (Julien et al., 2012) and is explored as a tumour marker in 409 
serological assays (CA72-4) (Reis et al., 2010).  410 
Despite the clinical relevance of STn in human malignancies, scarce information 411 
is available about its role in bladder tumours. Over twenty years ago, Langkilde et al. 412 
(Langkilde et al., 1992) addressed this antigen on series of transitional cell carcinomas 413 
(currently classified as high-grade urothelial cell carcinomas according to current WHO 414 
guidelines (Babjuk et al., 2012)). Normal mucosal biopsy specimens from patients with 415 
non-malignant bladder urologic diseases were included as controls. According to the 416 
authors, STn was not expressed by the control group, showed a very restricted pattern of 417 
expression in bladder tumours and no association with recurrence and progression. 418 
Subsequent in vitro studies found that mucins MUC1, MUC2 and MAUB (mucin 419 
antigen of the urinary bladder) isolated from bladder cancer cell lines carried STn 420 
(Bergeron et al., 1996; Bergeron et al., 1997). However, no evidence of such an 421 
expression was found in tumours. Herein, we readdressed this matter and found that the 422 
STn antigen was associated with advanced stage bladder tumours. More important, STn 423 
was absent in the healthy urothelium, which demonstrates its tumour-associated nature. 424 
Since this study was performed on a recent prospective series it is not possible, at this 425 
point, to determine correlations with disease outcome. Nevertheless, STn was mainly 426 
expressed by HG papillary NMIBC, known for their elevated risk of recurrence and 427 
progression to muscle invasive disease and MIBC that encompass an elevated risk of 428 
metastization and present decreased overall survival (Babjuk et al., 2012). STn 429 
expression was further associated with elevated Ki-67, a proliferation-related molecule 430 
and a surrogate biomarker of increased risk to recurrence and progression in bladder 431 
tumours (Margulis et al., 2009; Santos et al., 2003). In addition, the majority of non-432 
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proliferative tumours did not express STn, which demonstrates that the expression of 433 
the antigen is indeed a characteristic of proliferative tumours. Still, STn was mainly 434 
detected in non-proliferative areas of the tumours. However, the STn antigen was 435 
frequently observed in areas of invasion of the basal and muscle layers, suggesting it 436 
may be associated with the process of cell migration and invasion. This reinforces the 437 
notion that STn is part of a malignant bladder cancer phenotype, as previously observed 438 
for other carcinomas (Clement et al., 2004; Julien et al., 2006; Ohno et al., 2006; Ozaki 439 
et al., 2012; Pinho et al., 2007). We also found the STn antigen in tumour-adjacent 440 
mucosa, which may be explained by the migration of STn+ cells to the tumour 441 
surroundings. On the other hand, this may be a consequence of field carcinogenesis 442 
previously observed in bladder cancers (Jones et al., 2005; Palmeira et al., 2011). 443 
Nevertheless, the STn antigen holds potential as a biomarker of bladder disseminated 444 
disease.  445 
STn is a product of an incomplete O-glycosylation process due to the premature 446 
O-6 sialylation of the glycoside GalNAc1-O-Ser/Thr (Tn antigen) by ST6GalNAc.I 447 
(Marcos et al., 2004). In several epithelial tumours STn results from an increased 448 
ST6GalNAc.I expression and/or activity (Marcos et al., 2011; Sewell et al., 2006; 449 
Vazquez-Martin et al., 2004). Previous studies have reported ST6GalNAc.I expression 450 
by the urothelium at the mRNA level (Yamamoto et al., 2003); however we and others 451 
(Langkilde et al., 1992)  have not detected STn expression in the histologically healthy 452 
tissues. These observations suggest either the absence of the antigen or the insufficient 453 
sensitivity of the method. ST6GalNAc.I localization in the Golgi apparatus and the 454 
competitive action of other glycosyltransferases for the Tn antigen may also favour the 455 
extension of the O-glycan chain in non-pathological conditions. On the other hand we 456 
showed that the levels of STn in bladder tumours were correlated with the expression of 457 
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ST6GalNAc.I, supporting this as a major molecular mechanism underlying STn 458 
biosynthesis in these tumours. Few cases presented STn expression associated with a 459 
basal level of ST6GalNAC.I, meaning that other factors may contribute to promote the 460 
biosynthesis of STn. A disorganization of secretory organelles (Sewell et al., 2006), 461 
somatic mutations in the gene Cosmc, encoding a molecular chaperone essential for O-462 
chain elongation (Ju et al., 2008), the down-regulation/decreased activity of several 463 
other glycosyltransferases and/or the availability of sugar donors for biosynthesis, may 464 
also lead to STn overexpression. The integrated study of metabolic pathways, 465 
glycosyltransferases expression/activity, intra-cellular ultrastructures and 466 
microenvironmental changes may further enlighten the molecular events leading to 467 
abnormal O-glycosylation of bladder cancer proteins.   468 
In addition we have screened HT1376, 5637, T24 and MCR bladder cancer cell 469 
lines and found neglectable levels of the STn antigen (data not shown). The same was 470 
previously observed in gastric (Ozaki et al., 2012; Pinho et al., 2007) and breast 471 
(Clement et al., 2004; Julien et al., 2006; Julien et al., 2005) cancers cell models, 472 
demonstrating that tumour cells may lose the ability to express this antigen in vitro. 473 
Microenvironmental factors may play a determinant role in the induction of STn 474 
biosynthesis, yet these events remain unknown. Following the association of STn with 475 
invasive cases, we elected the invasive bladder cancer cell line MCR to evaluate the 476 
biological role of STn in these tumours. We started by stably transducing the MCR cells 477 
with ST6GalNAc.I, which resulted in the overexpression of STn. The expression of STn 478 
did not promote a significant enhancement of MCR cell proliferation, which is 479 
agreement with observations made for breast (Clement et al., 2004; Julien et al., 2006; 480 
Julien et al., 2005) and gastric cancer models (Pinho et al., 2007). These findings 481 
associated with the absence of the antigen from most bladder tumours non-proliferative 482 
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areas strongly suggests that STn expression does not play a direct role in tumour 483 
proliferation.    484 
On the other hand, STn expression significantly enhanced the migration and 485 
invasive capacity of MCR cells, demonstrating that this antigen plays an important role 486 
in bladder cancer cell invasion, as suggested by the observation of bladder tumours. 487 
Enhanced migration capabilities of STn+ cells on components of the extracellular 488 
matrix, such as fibronectin and collagen, have been described for other cancer cell lines 489 
(Julien et al., 2006; Julien et al., 2005; Pinho et al., 2007), and result, among several 490 
factors, from impaired integrin binding (Clement et al., 2004).  In addition, STn 491 
expression has been shown to increase the invasion potential of tumour cells (Clement 492 
et al., 2004; Julien et al., 2006; Ohno et al., 2006; Ozaki et al., 2012; Pinho et al., 2007), 493 
supporting a similar role in bladder tumours. Further experiments are however required 494 
to clarify the molecular mechanisms underlying promotion of cancer cell invasion and 495 
migration. These findings reinforce however that alterations in the glycosylation 496 
patterns of cell-surface proteins may strongly interfere with events like cell-cell 497 
adhesion, cell-matrix interaction, tumour growth, motility and invasion (Dall'Olio et al., 498 
2012).  499 
In resume, our work comprehensively describes the expression of the STn 500 
antigen in bladder cancer. Namely, it demonstrates the tumour-specific nature of this 501 
type of glycosylation and its association with advanced, highly proliferative tumours, 502 
invasion and organ disseminated disease. Thus, the evaluation of STn antigen may add 503 
valuable information about the aggressiveness of proliferative tumours, complementing 504 
the information given by Ki-67. Studies are ongoing in broader retrospective series to 505 
determine the association of STn with disease outcome and corroborate these findings. 506 
We are also devoted to the identification of the glycoproteins yielding STn, which is 507 
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expected to bring insights about the role of this type of glycosylation in bladder 508 
carcinogenesis and provide novel therapeutic vectors. The antigen STn may also be 509 
monitored noninvasively in urine or serum using as is the case for other human 510 
carcinomas using the CA72-4 test (Reis et al., 2010). This could allow decreasing the 511 
number of cystectomies in post-surgery follow-ups of patients with high-grade tumours, 512 
a particularly critical matter for the elderly that constitute the majority of the cases.  513 
Furthermore, the STn antigen is associated to high-grade NMIBC which 514 
currently constitutes one of the main therapeutics concerns due to their elevated risk of 515 
recurrence/progression (Babjuk et al., 2012). Adjuvant immunotherapy with BCG has 516 
allowed to delay recurrence and decrease the risk of progression into muscle invasive 517 
disease (Babjuk et al., 2012); still more than half of the patients either recur within two-518 
years after TUR of the tumour or show intolerance to the treatment (Askeland et al., 519 
2012; Yates and Roupret, 2011). Due to the lack of efficient therapies, upon therapeutic 520 
failure and/or muscle invasion, the patient is faced with cystectomy (Babjuk et al., 521 
2012).  522 
Carbohydrate antigens associated with advanced-stage tumours and malignant 523 
phenotypes such as STn, are expressed at the cell surface and, therefore, available for 524 
antibody or lectin-mediated recognition (Neutsch et al., 2012). Thus, these antigens may 525 
present an opportunity for the introduction of novel therapeutics, such as selective drug-526 
delivery approaches (Neutsch et al., 2012) or carbohydrate-based immunotherapy 527 
(Heimburg-Molinaro et al., 2011). An anti-cancer vaccine named Theratope, 528 
comprehending a synthetic STn coupled to the immunogenic carrier keyhole limpet 529 
haemocyanin has already been developed (Julien et al., 2009; Miles et al., 2011; 530 
Sandmaier et al., 1999). Tests in animal models and humans for breast, ovarian, and 531 
colorectal cancers have showed that the antigen is safe and produces a strong immune 532 
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response against these tumours (Julien et al., 2009; Julien et al., 2012; Miles et al., 533 
2011). Even though Theratope failed to improve overall survival of metastatic breast 534 
cancer patients in a phase III clinical study, the design of the study disregarded the 535 
heterogeneous STn expression between patients (Miles et al., 2011), compromising the 536 
outcome (Julien et al., 2012; Zeichner, 2012). Thus, Theratope or other STn-based 537 
vaccine designs may constitute valuable therapeutic options for STn positive advanced 538 
bladder tumours. However, given the low association of STn with more proliferative 539 
areas of the tumour, one is led to speculate that advanced stage bladder cancer patients 540 
may better benefit from the combination of anti-STn immunotherapy and anti-541 
proliferative drugs. Furthermore, these approaches may allow targeting disseminated 542 
disease in the adjacent and distant mucosa from the main tumour.  543 
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Table 1. STn expression in the healthy urothelium and in non-muscle invasive 556 
(NMIBC) and muscle invasive (MIBC) bladder cancers of different clinicopathological 557 
natures.  558 
  Total STn Expression 
   
Normal Urothelium 6  
-  6 (100%) 
+  - 
++  - 
+++  - 
   
Total STn+ 
 
0 (0%) 
   
NMIBC 50  
 
  
  
 
Low-grade papillary tumours 24  
-  19 (79%) 
+  5 (21%) 
++  - 
+++  - 
   
Total STn+ 
 
5 (21%) 
   
High-grade (CIS + papillary 
tumours) 26  
 
  
Carcinoma in situ (CIS) 5  
   
-  4 (80%) 
+  1 (20%) 
++   - 
+++  - 
 
  
Total STn+ 
 
1 (20%) 
   
high-grade papillary tumours 21 
 
   
-  5 (24%) 
+  9 (43%) 
++  4 (19%) 
+++  3 (14%) 
   
Total STn+  16 (76%) 
   
MIBC 19  
-  5 (26%) 
+  11 (58%) 
++  2 (11%) 
+++  1 (5%) 
   
Total STn+  14 (74%) 
   
 559 
-: no reactivity; +: 15%; ++: 15-30%; +++: 30%-45% of the tumour 560 
 561 
 562 
 563 
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Figure captions 564 
 565 
Figure 1. Expression of STn in FFPE bladder tumours. A) Low-grade papillary 566 
tumour showing a predominance of STn+ cells in the basal layer; B) Magnification 567 
which shows tumour cells with membrane and cytoplasmic STn+ staining; C) High-568 
grade papillary tumour evidencing the focal nature of STn expression. Positive cells 569 
were found both in the basal layer and throughout the papillae; D) High-grade papillary 570 
tumour showing locally extensive STn positivity; E) High-grade papillary tumour 571 
evidencing STn+ in the basal layer; F) CIS showing STn+ in the cells facing the lumen 572 
of the bladder; G) MIBC showing locally extensive STn expression including at the 573 
muscle invasive front; H) MIBC highlighting STn+ cells invading the muscle layer. 574 
 575 
Figure 2. Association between STn expression and HG NMIBC and MIBC. The 576 
percentage of STn+ tumours was higher in HG when compared to LG and also in MIBC 577 
when compared to NMIBC (LG+HG). “*” p=0.03; “**” p=0.002 (Chi-square Test). 578 
 579 
Figure 3. Expression pattern of STn in radical cystectomy specimens. Radical 580 
cystectomy specimens have been organized based on histological grade. They include 581 
the tumour responsible by the therapeutic decision termed “main tumour” (MT), an 582 
adjacent (AM) and distant mucosa (DM). The graphical matrix highlights that, 583 
whenever STn is expressed by the main tumour (13/16; 63%), it is always present in the 584 
adjacent mucosa (13/13, 100%). One preneoplastic and one neoplastic distant mucosa 585 
also expressed the antigen.  586 
 587 
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Figure 4. Association between ST6GalNAc.I and STn expression in LG and HG 588 
bladder tumours.  The graph shows that ST6GalNAc.I expression is increased in STn+ 589 
tumours and increases further for more elevated STn expressions (>15-30% of the 590 
tumour section). This suggests that the overexpression of ST6GalNAc.I is one of the 591 
main mechanisms underlying the presence of STn in bladder cancers. Furthermore, it 592 
shows this event occurs in both LG and HG tumours. “*” p<0.05; “**” p<0.01 593 
(Student’s T-test) 594 
 595 
Figure 5. Expression of STn and Ki-67 in bladder tumours. A) Graphical Matrix 596 
highlighting the association between proliferative tumours (Ki-67>18%) and STn 597 
expression in bladder tumours. HG NMIBC and MIBC were considered to be 598 
proliferative tumours and a significant association was found between STn expression 599 
and tumours presenting proliferation phenotypes (p<0.001; Chi-square Test). The 600 
notation “Ki-67/STn” in the column more to the right refers to tumours presenting areas 601 
that appear to exhibit cells expressing both Ki-67 and STn. B) Immunohistochemistry 602 
for Ki-67 and STn highlighting Ki-67-/STn+; Ki-67+/STn-; and Ki-67+/STn+ areas.    603 
 604 
Figure 6. ST6GalNAc.I mRNA expression and sialyltransferase activity in bladder 605 
cancer MCR cell lines. A) ST6GalNAc.I expression and activity in MCR cell lines. 606 
The relative mRNA levels of ST6GalNAc.I (open bars) and sialyltransferase activity 607 
towards ABSM (gray bars) were analyzed as described in the Material and Methods 608 
section. Both, ST6GalNAc.I mRNA and sialyltransferase activity towards ABSM are 609 
negligible in negative control cells and markedly increased upon ST6GalNAc.I 610 
transduction. B) Flow cytometry analyses of transduced MCR cells. Both negative 611 
control (MCRnc in grey histogram) and ST6GalNAc.I-transduced (MCRSTn+ in open 612 
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histogram) cell lines were stained with the secondary antibody anti-Ig’s-FITC following 613 
incubation with the primary antibody anti-STn antigen. 90% of the ST6GalNAc.I-614 
transduced cells expressed the STn antigen (MFI = 216). The data are shown as a mean 615 
± standard deviation of 3 independent studies. “*” p<0.05, “**” p<0.01 (Student’s T-616 
test) 617 
 618 
Figure 7. Comparison between the proliferation capacity of MCRnc and 619 
MCRSTn+ cells. The transduced MCR cells were labelled with CFSE and cultured for 620 
various periods of time (48, 72 and 96 hours). The cells were harvested and analyzed by 621 
flow cytometry with Modfit software, allowing the calculation of the proliferation 622 
index, which represents the average number of cells that was originated by a single cell 623 
of the parent generation. At the various periods of culture, MCRSTn+cells show a 624 
higher proliferation index than the negative control, but this difference was only 625 
statistically significant at 72 hours of culture. The data are presented as a mean ± 626 
standard deviation of 3 independent studies. “*” p<0.05 (Student’s T-test) 627 
 628 
Figure 8. STn expression promotes MCR cells wound healing closure and invasion. 629 
A) Wound healing closure assay. Uniform scratches were made using a 200μL pipette 630 
tip in confluent monolayers of MCRSTn+ and MCRnc cells. Cells were allowed to heal 631 
and the extent of closure was monitored by microscopic analysis. After 24 hours 632 
culture, the MCRSTn+ cells had almost completely covered the wound, in clear contrast 633 
to negative control, MCRnc, where unoccupied space was still observed. B) Invasion 634 
assay. MCRSTn+ and MCRnc cells were incubated for 24h, in the upper compartment 635 
of Matrigel invasion chambers, in complete DMEM medium and in the absence of other 636 
chemoattactants. Invasive cells were determined as described in Materials and Methods. 637 
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The data are presented as a mean ± standard deviation of 4 independent studies. “*” 638 
p<0.001 (Student’s T-test). 639 
 640 
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